Chin up on ImmunoCellular board
This article was originally published in Scrip
Executive Summary
Los Angeles-based oncology company ImmunoCellular Therapeutics has elected Dr Richard Chin to its board of directors, and made him chair of the company's compensation committee and a member of the audit committee. Dr Chin currently serves on the Adjunct Faculty of the University of California San Francisco School of Medicine, and on the boards of Genmedica Therapeutics, Balance Therapeutics and Galena Biopharma. He was previously CEO of OneWorld Health and president and CEO of OXiGENE.